CD274 and mismatch repair cancer syndrome 1: In a study on recurrent or metastatic colorectal cancer patients with MMR deficiency or high MSI, nivolumab showed an objective response rate of 31.1, and 69% of the patients had a disease control rate of ≥12 weeks, which indicated that patients with high MMR deficiency or high MSI might exhibit better responses to PD-1/PD-L1 blockade therapy [40, 83].